AHEAD A3 (NCT04468659) is a Phase III preclinical-AD lecanemab trial in cognitively-unimpaired adults with intermediate amyloid; eligibility uses APOE genotype stratification, with the 2022 SAP amendment refining APOE4-positive arm allocation in line with APOE4-specific BBB/pericyte evidence.

Evidence span

AHEAD A3 (NCT04468659) is a Phase III preclinical-AD lecanemab trial in cognitively-unimpaired adults with intermediate amyloid; eligibility uses APOE genotype stratification, with the 2022 SAP amendment refining APOE4-positive arm allocation in line with APOE4-specific BBB/pericyte evidence.

Method & conditions

Evidence type

observational

Method

manual state transition; placebo-controlled clinical trial where source reports control arm

Species

Homo sapiens

Conditions

Human, cognitively unimpaired adults aged 55-80, intermediate amyloid by PET. APOE-stratified primary efficacy. Trial-protocol amendment in 2022 narrowed APOE4-positive arm allocation reflecting accumulated APOE4-specific BBB evidence.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required